Ex vivo generation of human cytomegalovirus-specific cytotoxic T cells by peptide-pulsed dendritic cells

被引:59
作者
Kleihauer, A
Grigoleit, U
Hebart, H
Moris, A
Brossart, P
Muhm, A
Stevanovic, S
Rammensee, HG
Sinzger, C
Riegler, S
Jahn, G
Kanz, L
Einsele, H
机构
[1] Univ Tubingen, Med Klin 2, D-72076 Tubingen, Germany
[2] Univ Tubingen, Inst Zellbiol, D-72076 Tubingen, Germany
[3] Univ Tubingen, Inst Med Virol, D-72076 Tubingen, Germany
关键词
HCMV; adoptive immunotherapy; allogeneic stem cell transplantation; dendritic cells; peptides;
D O I
10.1046/j.1365-2141.2001.02681.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Adoptive transfer of donor-derived human cytomegalovirus (HCMV)-specific T-cell clones can restore protective immunity after stem cell transplantation. Ex vivo induction of HCMV-specific T cells using HCMV-infected fibroblasts as stimulator cells confines this approach to HCMV-seropositive donors and requires the presence of infectious virus during the stimulation procedure. In this study, we describe a potential alternative strategy to generate HCMV-specific T cells ex: vivo for adoptive immunotherapy. Generation of HCMV-specific cytotoxic T lymphocytes (CTLs) ex vivo was investigated using peptide-pulsed dendritic cells as antigen-presenting cells. HCMV-specific T cells were generated and sufficiently expanded for adoptive immunotherapy in 6 out of 14 HCMV-seropositive and 2 out of 11 HCMV-seronegative donors. The CTLs recognized HCMV-infected autologous fibroblasts. No lysis was observed with either non-infected autologous or HLA-mismatched infected fibroblasts, Staining with tetrameric HLA/peptide complexes revealed significant enrichment for peptide-specific T cells of up to 28% and >90% of CD8(+) T cells after three and five specific stimulations respectively. In addition, the expansion rates indicated that ex: vivo generation of >1 x 10(9) HCMV-specific T cells was possible after 6-7 weeks when cultures were initiated with 1-5 x 10(6) responder cells. Thus, the approach with peptide-pulsed DCs to generate HCMV-specific CTLs is feasible for clinical application after allogeneic stem cell transplantation.
引用
收藏
页码:231 / 239
页数:9
相关论文
共 36 条
[1]   Phenotypic analysis of antigen-specific T lymphocytes [J].
Altman, JD ;
Moss, PAH ;
Goulder, PJR ;
Barouch, DH ;
McHeyzerWilliams, MG ;
Bell, JI ;
McMichael, AJ ;
Davis, MM .
SCIENCE, 1996, 274 (5284) :94-96
[2]  
BEDNAREK MA, 1991, J IMMUNOL, V147, P4047
[3]   Time-resolved fluorometric assay for natural killer activity using target cells labelled with a fluorescence enhancing ligand [J].
Blomberg, K ;
Hautala, R ;
Lovgren, J ;
Mukkala, VM ;
Lindqvist, C ;
Akerman, K .
JOURNAL OF IMMUNOLOGICAL METHODS, 1996, 193 (02) :199-206
[4]   Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients [J].
Boeckh, M ;
Bowden, RA ;
Gooley, T ;
Myerson, D ;
Corey, L .
BLOOD, 1999, 93 (05) :1781-1782
[5]   Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies [J].
Brossart, P ;
Heinrich, KS ;
Stuhler, G ;
Behnke, L ;
Reichardt, VL ;
Stevanovic, S ;
Muhm, A ;
Rammensee, HG ;
Kanz, L ;
Brugger, W .
BLOOD, 1999, 93 (12) :4309-4317
[6]  
Brossart P, 1998, CANCER RES, V58, P732
[7]  
DAVENPORT MP, 1995, IMMUNOGENETICS, V42, P392
[8]   Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection [J].
Diamond, DJ ;
York, J ;
Sun, JY ;
Wright, CL ;
Forman, SJ .
BLOOD, 1997, 90 (05) :1751-1767
[9]  
EINSELE H, 1995, BLOOD, V86, P2815
[10]   Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection [J].
Einsele, H ;
Hebart, H ;
Kauffman-Schneider, C ;
Sinzger, C ;
Jahn, G ;
Bader, P ;
Klingebiel, T ;
Dietz, K ;
Löffler, J ;
Bokemeyer, C ;
Müller, CA ;
Kanz, L .
BONE MARROW TRANSPLANTATION, 2000, 25 (07) :757-763